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A mechanism can be defined as an explanation of an observed phenomenon that explains the
processes underlying the phenomenon in terms of events at lower levels of organization. A
prerequisite for new, more mechanistic, approaches, which would use in vitro systems rather
than conventional animal analogy models, is a strengthening of the underlying scientific basis of
toxicity testing. This will require greater recognition of the differences between fidelity and
discrimination models and between analogy and correlation models. The development of high-
fidelity, high-discrimination tests with a sound mechanistic basis will also require greater
appreciation of the interdependence of all the components of test systems and the development
of new alternative (i.e., nonanimal) testing strategies that can provide the specific knowledge
needed for making relevant and reliable predictions about the potential effects of chemicals and
products in human beings. The optimal use of this new knowledge will require fundamental
changes to current practices in risk assessment. - Environ Health Perspect 106(Suppl
2):453-457 (1998). http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl-2/453457balls/abstract.html
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Introduction
There is currently much discussion about
the need for mechanistic tests, although it
is not always clear what this term means.
For example, mechanistic tests could mean
tests involving biologic systems with a
mechanistic basis that is understood, or
tests that are able to identify those effects
mechanistically related to the in vivo effects
to be predicted.
In fact, calls for more mechanistic
approaches include a wide spectrum of
thoughts, from "We must try to make toxic-
ity testing more scientific" or "We need a
specific test for the interaction with this type
ofreceptor on this type ofcell" to "We need
a test for identifying chemicals that inhibit
the activityofthis particular enzyme."
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Significant improvements to the scien-
tific basis of toxicity tests and to strategies
for the application ofthe information they
provide are needed before we can hope to
develop new mechanistic tests (indeed, new
tests ofanykind) ofanysignificance.
Art or Science?
Some toxicologists [e.g., Dayan (I)] argue
that toxicity tests should not be seen as sci-
entific experiments in the usual sense, and
because ofthe generality and inevitable lack
ofrigor ofsuch tests, they should be consid-
ered metascience rather than true science.
Roberfroid (2) is less willing to accept
this contrast between what he calls the sci-
ence of toxicology and the art of toxicity
testing. He questions the acceptability of
the current reliance ofrisk assessment on a
poor understanding ofmechanisms oftoxi-
city, on questionable theoretical models
(e.g., the two-step hypothesis of carcino-
genicity), or on controversial and unsub-
stantiated assumptions (e.g., the ability ofa
linear dose-effect relationship to support
the extrapolation of extremely high-dose
effects to low-dose effects). Roberfroid
argues that new scientifically sound, mech-
anism-based tests are needed that take into
account the most relevant molecular and
cellular events that play a role in the toxic-
ity of chemicals, and that such tests will
inevitably involve batteries of replacement
alternative (i.e., nonanimal) test methods.
Meanwhile, a good example of the
difference between the true science oftoxi-
cology and the metascience oftoxicity test-
ing has recently been published. Ashby and
his colleagues (3) wanted to establish that
acetochlor, an herbicide of commercial
importance, does not pose a genotoxic or
carcinogenic hazard to humans despite the
detection of some genotoxic effects and
benign tumors in rats that were given the
chemical at the maximum tolerated dose.
An enormous but unspecified number of
animals, as well as considerable human and
other resources, were used in true scientific
toxicology studies made necessary by
embarrassing results provided by metasci-
entific tests. The conclusion was that the
effects in the rats were not relevant to
humans; that is the heart of the problem.
Laboratory animals will always be imper-
fect models, and the relevance of the data
provided by routine regulatory tests can
almost never be known, as studies such as
those conducted by Ashby et al. (3) can
rarely be afforded. That is why large safety
factors are often used in risk assessment in
an attempt to allow for inaccuracies due to
species differences, high-dose to low-dose
extrapolation, etc. (4).
Progress will also be limited unless
toxicologists are prepared to address the con-
sequences of irrational high-dose regimes.
The following comment by Ashby et al. (3)
about their own work provides a warning:
"At these elevated dose levels, associated tis-
sue changes were encountered that compro-
mised interpretation and extrapolation of
the toxicities observed to lower dose levels-
in particular, to those levels of exposure
likely to be encountered by humans."
Chamberlain (5) has put forward the
case for the development of new proce-
dures for risk assessment based on replace-
ment alternative test data, which will mean
making significant changes to the regula-
tory process itself. This will require a more
rational and more critical approach to haz-
ard prediction and risk assessment than is
fashionable at present. Ifnew methods pro-
vide us with better data, we must optimize
the uses to which we put them. This in
turn will require better understanding of
the nature of models and of the strengths
and limitations ofthe kinds ofinformation
they can provide.
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Fidelity, Discrimination,
Analogy, Mechanism,
and Correlation
Fidelity is the accuracy with which a model
reproduces the overall properties ofwhat is
being modeled, whereas discrimination is
the accuracy with which a model repro-
duces a particular property or properties of
what is being modeled.
No model can offer 100% fidelity or
100% discrimination, but the best models
will have the highest possible fidelity in
combination with the highest possible
discrimination. In general, a low-fidelity/
high-discrimination model is more likely
to be useful than a high-fidelity/
low-discrimination model.
Russell and Burch (6) warned of the
high-fidelity fallacy, to expose the weakness
of the following kind of argument:
"Humans are mammals, so other mammals,
such as monkeys, dogs or rats, are better
models of humans than are other organ-
isms, such as birds, fish, insects or bacteria."
The problem is that high fidelity does not
mean high discrimination. For example,
certain chemicals induce peroxisome prolif-
eration in rats, which is linked with the
induction of tumors. Therefore, according
to high-fidelity reasoning, rat peroxisome
proliferators may be human carcinogens
because ofthe overall similarity ofrats and
humans. However, this is unlikely because
the chemicals that induce peroxisome pro-
liferation in rats do not appear to do so in
humans. In this instance the rat is a low-
discrimination model despite its overall
relatively high fidelity.
It is possible that chemicals that cause
peroxisome formation in rats might inter-
act with a specific receptor in humans and
initiate tumor formation. If so, the rela-
tionship between this chemical-receptor
interaction in humans and peroxisome for-
mation in rats would have to be satisfacto-
rily established before the rat could be
accepted as a suitable model for identifying
chemicals that actvia such a mechanism.
The assumed relevance ofanimal tests is
based on the general high fidelity ofanimal
models, i.e., on analogy (where similarity in
a particular circumstance is inferred from
agreement or similarity in an acceptable
number of other features in the systems
beingcompared) rather than on mechanism
(where similarity is based on an adequate
knowledge of the mechanistic basis of the
phenomenon under consideration and its
operation in the systems beingcompared).
In any case, similarity does not mean
identity, so judgment in the interpretation
of the meaning of data will always be
necessary, whatever the model maybe.
Correlative approaches are based solely
on statistical relationships between those
phenomena that cannot be explained on a
mechanistic basis. They are unlikely to lead
to correlative tests that will receive wide-
spread acceptance, even iftheywould likely
be more useful than current animal analogy
tests lacking a sound mechanistic basis.
Qualitative and quantitative structure-
activity relationship (SAR) models represent
correlative approaches, but mechanistic SAR
approaches are possible, e.g., when interac-
tions with specific receptors can be pre-
dicted from structure and the consequences
ofsuch interactions are understood.
Greater recognition of these truths
would lead to a more rational view of the
value ofanimal procedures and improve the
prospects for nonanimal tests. Animal mod-
els will always be limited by inescapable
species differences, and mechanistic studies
in animals are so prohibitively expensive
that only a small number of compounds
could ever be tested in this way. Replace-
ment alternative methods offer the possibil-
ity of greater relevance based on better
science, e.g., through mechanistic tests on
human material.
High-Fidelity and
Mechanistic Tests
There can also be confusion over whether
a high-fidelity test is a mechanistic test.
For example, the use ofwhole rat embryos
in vitro is an example of a high-fidelity
model, as the cultured embryos are similar
to rat embryos in utero. Thus, when
whole-embryo cultures are used to screen
chemicals for teratogenicity according to a
number of specified, relevant end points,
we have a high-fidelity test. We do not
have a sufficient understanding ofthe cel-
lular or molecular basis of teratogenicity
for this to be a mechanistic test. Whether
it is acceptable as a high-discrimination
test will depend on the outcome of a
formal validation study such as the one
being managed by the Zentralstelle zur
Erfassung und Berwetung von Ersatz- und
Erganzungsmethoden zum Tierversuch
under contract to the European Centre for
the Validation ofAlternative Methods (7).
A mechanism has been defined as "an
explanation of an observed phenomenon,
which explains the processes underlying the
phenomenon in terms of events at lower
levels oforganisation" (8). For example:
Paracetamol (acetaminophen) over-
dosage can lead to death in humans;
the mechanism is death as a result of
hepatic failure.
* Hepatic failure as a result of paraceta-
mol overdosage in turn results from
hepatotoxicity.
* The presumed mechanism of hepato-
toxicity is metabolism ofparacetamol
to N-acetyl-p-benzoquinoneimine.
* The presumed mechanism of hepato-
toxicity of N-acetyl-p-benzoquino-
neimine is covalent binding to
macromolecules.
* Covalent binding to macromolecules
presumably results in impairment of
the functions of those molecules, lead-
ing to cell toxicity, hepatic failure, and
death ofthe patient.
A mechanistic test is based on a system
at an acceptable level oforganization and a
relevant end point based on a sufficient
understanding ofthe cellular and/or mole-
cular basis of the effect under consid-
ertion. An example is a test based on a
critical or pivotal stage in the development
of an effect, such as interaction with a
defined receptor.
Mechanistic tests are the tests most
likely to be high-discrimination tests, but
the fidelity ofthe system must also be borne
in mind. For example, the Salmonella
typhimurium test is a relatively high-
discrimination test for genotoxicity, but a
liver S9 fraction must be incorporated to
improve its fidelity, i.e., its ability to detect
metabolism-mediated genotoxicity.
In contrast, the S. typhimurium test is
only a low-fidelity, low-discrimination test
for nongenotoxic carcinogens.
The Components
ofTest Procedures
The purpose ofa test procedure is to gain
relevant and reliable information about a
defined set of circumstances as a basis for
makingdecisions about further action.
Toxicity test procedures can have the
following components: a biologic system;
an end point, which refers to the processes,
responses, or effects assessed; an exposure
regimen; an end point measurement,
which refers to the techniques used to
assess end points; a data analysis method
and awayofexpressing the result; a predic-
tion model, which is the tool used to con-
vert the results from a test into a prediction
oftoxicity in vivo; and a means ofexpress-
ing toxic hazard (a quantitative expression
ofthe adverse effects elicited by a chemical
under defined conditions ofexposure).
The expression ofhazard obtained from
the performance of a relevant and reliable
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test can be used in risk assessment. Risk is
the probability that an event will occur
given a particular condition of exposure
[Figure 1; (9)]. It is expressed as the prod-
uct of the hazard and the likelihood of
exposure, where exposure is estimated for a
specific population.
It must be recognized that the quality
of the eventual risk assessment is entirely
dependent on the strength (i.e., the rele-
vance and reliability) ofeach component of
the test procedure. A test cannot be better
than its-weakest component.
NewTest Development
and Validation
Validation is the process whereby the
reliability and relevance ofa procedure are
established for a particular purpose (10). It
is a question ofdemonstrating the scientific
integrity and practical usefulness of new
methods and their application. The rele-
vance of the test method and the predic-
tion model must be evaluated separately, as
must their combination as a test procedure.
There is now wide international agree-
ment that formal validation should be a cru-
cial and unavoidable step between new test
development and regulatory acceptance.
The concepts of prevalidation and predic-
tion models are currently being refined to
Properties oftest + Properties of
material biologic target
systems
Biokinetic factors
Effect/response
Route
Dose
Frequency
End point/measurement
Timing
Hazard predictions
Likelihood of exposure
Conditions of exposure
Risk assessment
Risk avoidance
Risk limitation
Risk management
Figure 1. Testing, hazard prediction, and risk assess-
ment. Data from Balls and Fentem(8), with permission
ofthe Fund forthe Replacement ofAnimals in Medical
Experiments.
improve the quality and speed of formal
validation. The stages in the evolution of
new tests (9) are as follows:
Test development (laboratory oforigin)
* Purpose ofthe test
* Need for the test
* Derivation ofthe method
* Application to appropriate chemicals
* Case for inclusion in avalidation study
* Production ofa protocol
* Development ofa prediction model
Prevalidation (informal interlaboratory
study)
* Optimization ofthe test protocol
* Assessment of its interlaboratory trans-
ferability
* Optimization ofthe prediction model
Validation (formal interlaboratory study,
induding a blind trial)
* Two phases: preliminary phase (training
set of chemicals) and definitive phase
(test set ofchemicals)
* Main stages: study design; selection of
tests and laboratories; selection, distribu-
tion, and testing ofchemicals; data col-
lection and analysis; and assessment of
performance of test and ofapplicability
ofprediction model
Independent assessment (of study and
proposals)
Progression toward regulatory acceptance
It is commonly believed that validation
is the limiting step in the acceptance ofnew
test methods. However, it is now becoming
dear that, in fact, the main limiting factor
is new test development.
Recently Purchase (11) stated:
The whole validation process is designed
to provide very specific answers to ques-
tions such as: "Will the method predict
toxicity qualitatively?" or "Will the
method predict toxicity quantitatively?"
In that respect there is a close analogy
with the development ofa new chemical
product: once the new compound is
synthesized, the steps of development
until it is commercialised can be pre-
dicted to a certain degree. The work of
method validation is akin to technology
development.
Test development is much less pre-
dictable. It is closer to the definition of
a scientific activity in that the outcome
of research is unpredictable, both in
terms of content and time. To develop
methods to predict a particular toxic
consequence with precision requires
that the mechanism of action which
leads to the toxic effect is understood. A
good example is the Ames' Salmonella
mutation method which has a precise
mechanistic basis for its performance.
Its development relied on many years of
understanding of genetics of Salmonella
and the recognition of the mechanism
of mutation induction before there was
a realistic chance of a satisfactory
method. Thus, test development will
depend not only on the attention given
by individual scientists to developing
methods but also to the scientific
advances over a wide area of biology.
Identifying new areas ofbiology ripe for
exploitation and having insight into the
mechanisms oftoxicity will be the limit-
ing steps in test development, where the
really innovative step is the synthesis of
the development process, although no
less demanding in terms of effort and
dedication, has as its main objective to
ensure that its properties are suitable for
its intended use. Thus the distinctive
feature ofproduct development is at the
invention stage. (11)
Existing Tests, NewTests,
and Knowledge Needed
Much has been written about difficulties
experienced in finding in vivo data ofsuffi-
ciently high quality and relevance for use
in the development and validation of in
vitro tests. This is partly because industrial
companies want to keep confidential what
they consider their own property.
There is, however, another problem. If
the data from an animal test are themselves
of limited usefulness in terms of the pur-
pose ofthe test, i.e., for predicting the like-
lihood of particular effects in human
beings, those data must be oflimited utility
as a basis for evaluating the reliability of in
vitro test data for predicting the likelihood
ofthose effects in human beings.
It is therefore essential that there is a
regular, thorough, and objective review of
all animal test methods in light ofthe pur-
poses for which they are used. This in turn
means that there must be an objective
analysis ofthose purposes.
If we intend to use tests to provide
essential knowledge as a means ofdevelop-
ing the safest, most effective products pos-
sible, we must first define more precisely
the knowledge required. If another goal is
to develop valid nonanimal test procedures
for providing that knowledge, we must
decide how these new test procedures
should be validated. If the existing animal
test is reliable and relevant in providing the
necessary knowledge, data from that test
can be used in the validation of potential
replacement alternative methods. Ifnot, no
attempt should be made to use such data in
the validation of new tests. In those cir-
cumstances, the only way forward is to
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establish a convincing relationship between
the information that can be provided by
the nonanimal test procedure and the
knowledge needed to predict likely effects
in human beings.
Regulatory authorities and many
toxicologists in industry are apprehensive
about having to change the practices to
which they have long been accustomed,
however unscientific and inadequate they
may be. Happily, others are more progres-
sive, indudingPioda (12), a Swiss regulator,
who made the following statement at a con-
ference in Zurich in 1993, on "Alternatives
to Animal Testing: New ways in the
Biomedical Sciences, Trends and Progress":
It should not be forgotten that real
alternatives are in essence revolutions,
and revolutions cannot be incorporated
into an existing structure. All our laws
are based on animal experiments.
Therefore, it should be acknowledged
that the existing structure will have to
be changed before something revolu-
tionary can be introduced. These
thoughts are particularly directed at
those who are involved in the prepara-
tion and revision oflaws. Ifthis revolu-
tionary seed of new methods is so
important for the classification of
chemicals, then the philosophy of the
laws should be changed in accordance.
Without this essential change, a break-
through will never be achieved. (12)
Testing, Hazard Prediction,
and RiskAssessment
Quantitative risk assessment (QRA) models
have been used since the 1950s for estimat-
ing carcinogenic risks from environmental
pollutants, particularly in the United
States. Approximately six mathematical
models are in use currently (e.g., probit,
logit, and multistage models), the basis of
which is the application of mathematical
equations to the tumor incidence derived
experimentally from long-term, typically
rodent, carcinogenicity studies. A QRA
equation is derived from measurements of
the pharmacodynamics and kinetics ofthe
substance in animals in combination with
scaling factors. The additional use ofsafety
factors is highly subjective and as a result,
assessments based on a QRA may be in
error by several orders ofmagnitude. Such
models could possibly be validated retro-
spectively to some extent byusingepidemi-
ologic methods. However, this would be
limited to studies of hazardous chemicals
that have been present previously in the
environment, where subgroups ofthe pop-
ulation with different histories ofexposure
could be identified.
Mathematical models may have the
potential to make risk analyses more accu-
rate, but such sophisticated techniques are
not necessarily of any real value. Risk
assessment is crucially dependent on the
validity ofthe scientific assumptions made
and the relevance and reliability ofthe tox-
icology data used. Nevertheless, however
sophisticated the analysis may be, rats and
dogs are not human beings. Therefore, in
many cases mathematical models may only
serve to make the assessment deceptively
precise, and the conservatism of the
approach currently used precludes any
proper evaluation ofthe use ofmathemati-
cal models in risk assessment. At the pre-
sent time, nonspecific models based on
assumptions, which may or may not be
scientifically correct, are used for risk
assessment. In the future we should attempt
to use a quantitative, more mechanistic
approach whenever possible.
This is particularly true, for example,
in the case oftests for human carcinogens.
The insuperable problem ofspecies differ-
ences and the bizarre use ofrepeated, very
high dose exposure regimes inevitably lead
to a questioning of the scientific rationale
and merit of the traditional rodent bioas-
say and of the value of any predictions
based on it. There has been a revolution in
concepts of carcinogenesis. This must be
taken into account in new test develop-
ment, which must in turn include strate-
gies based on molecular and cell biology
and on the emerging understanding of
the carcinogenic process. Nowhere are
theoretical and practical mechanistic
approaches more necessary.
Concluding Comments
The following are among the points to be
actively taken into account ifwe want to
improve the scientific basis oftoxicity tests
and testing strategies:
* Agreement must be reached on what is
understood and encompassed by the
term mechanistic approaches.
* Approaches to toxicity testing, and to
new methods in particular, must be
based on a better understanding of
normal physiologic and toxicologic
processes.
* The development of mechanistically
based tests will therefore be dependent
on progress in the science oftoxicology.
* Emphasis should be placed on high-dis-
crimination tests rather than on high-
fidelity models.
* The application of new approaches
must be based on integrated testing
strategies involving, for example, in
vitro and quantitative SAR procedures
rather than on animal models. Mechan-
istic approaches with animal models are
too difficult and costly and are of
questionable relevance where the assess-
ment of risk to humans is the ultimate
objective.
* Such new mechanistic approaches are
likely to require fundamental changes
to current practices in riskassessment.
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